Journal
JOURNAL OF NEURO-ONCOLOGY
Volume 123, Issue 3, Pages 441-448Publisher
SPRINGER
DOI: 10.1007/s11060-015-1837-7
Keywords
Vaccine; Heat shock protein; Glioblastoma; Glioma; Immunotherapy; Clinical trial
Categories
Funding
- NCI NIH HHS [R01 CA164714, P30 CA060553] Funding Source: Medline
- NIGMS NIH HHS [T32 GM008152] Funding Source: Medline
- NINDS NIH HHS [R00 NS078055] Funding Source: Medline
Ask authors/readers for more resources
Current adjuvant treatment regimens available for the treatment of glioblastoma are widely ineffective and offer a dismal prognosis. Advancements in conventional treatment strategies have only yielded modest improvements in overall survival. Immunotherapy remains a promising adjuvant in the treatment of GBM through eliciting tumor specific immune responses capable of producing sustained antitumor response while minimizing systemic toxicity. Heat shock proteins (HSP) function as intracellular chaperones and have been implicated in the activation of both innate and adaptive immune systems. Vaccines formulated from HSP-peptide complexes, derived from autologous tumor, have been applied to the field of immunotherapy for glioblastoma. The results from the phase I and II clinical trials have been promising. Here we review the role of HSP in cellular function and immunity, and its application in the treatment of glioblastoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available